NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Switzerland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-2.51M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -25.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.51 |
| Price-to-Book | 2.83 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.38M |
| Float | $2.61M |
| % Insiders | 68.06% |
| % Institutions | 1.14% |
Volatility is currently contracting
The appointment follows New c elX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101 , providing a clear regulatory pathway toward clinical trials
FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug (“Pre-IND”) briefing package to the U.S. Food and Drug Administration (“FDA”) to support the proposed First-In-Human (“FIH”) clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (“Eledon”; Nasdaq: ELDN).
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy.
